Business Context and Reporting Period
This Form 8-K Current Report was filed by Salarius Pharmaceuticals, Inc. (not Decoy Therapeutics Inc.) on May 11, 2023, with the report date of May 11, 2023. The filing details a private placement offering that closed on May 16, 2023. The Company is a Delaware corporation with its principal executive offices in Houston, Texas, and its common stock trades on The Nasdaq Capital Market under the symbol "SLRX."
Key Financial Metrics and Transaction Details
The filing reports a capital raise transaction rather than standard operating financial metrics (revenue, profit, cash flow, or margins are not provided in this document).
- Aggregate Gross Proceeds: Approximately $6.0 million (exclusive of fees and expenses).
- Securities Issued:
- 330,000 shares of Common Stock at $1.65 per share.
- Pre-Funded Warrants to purchase up to 3,306,364 shares at $1.6499 per warrant.
- Series A-1 Warrants to purchase up to 3,636,364 shares at an exercise price of $1.40 (5.5-year term).
- Series A-2 Warrants to purchase up to 3,636,364 shares at an exercise price of $1.40 (18-month term).
- Placement Agent Fees: H.C. Wainwright & Co., LLC received a cash fee of 7.0% of gross proceeds, a 1.0% management fee, $65,000 for non-accountable expenses, and warrants to purchase up to 254,545 shares at $2.0625 per share.
Material Changes and Restrictions
The transaction represents a material change in the Company's capital structure through the issuance of new equity and warrants. The Securities Purchase Agreement includes significant restrictions on future issuances:
- 90-Day Lock-up: The Company is prohibited from issuing or announcing the issuance of Common Stock or equivalents for 90 days after the registration statement effectiveness, with limited exceptions.
- One-Year Variable Rate Ban: For one year following the registration statement effectiveness, the Company is prohibited from entering into variable rate transactions (e.g., securities with conversion prices based on future trading prices or subject to reset).
- Beneficial Ownership Limit: The Investor cannot exercise warrants if it would cause beneficial ownership to exceed 4.99% (or 9.99% at the Investor's option) of outstanding Common Stock.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, revenue outlook, or management commentary regarding business operations. Key contingencies and risks identified include:
- Registration Rights: The Company must file a registration statement within 15 calendar days and use best efforts to have it declared effective within 45 days (or 75 days if a full SEC review is required).
- Liquidated Damages: Failure to meet filing or effectiveness deadlines may require the Company to pay liquidated damages to the Investor.
- Dilution: The issuance of shares and warrants, including the placement agent warrants, will result in dilution to existing shareholders.
Investor Verification Checklist
- Verify the exact closing date of the offering (May 16, 2023) and the final net proceeds after deducting the 7.0% placement fee and other expenses.
- Confirm the total number of shares outstanding post-closing to calculate the dilution impact of the 330,000 shares and the warrant coverage.
- Review the filed registration statement (S-1 or S-3) to ensure the Company meets the 15-day filing and 45-day effectiveness deadlines to avoid liquidated damages.
- Check subsequent filings for any updates on the Company's cash runway and burn rate, as this 8-K does not provide current liquidity metrics.